To receive future news releases direct to your inbox, subscribe by emailing email@example.com.
Historical news and financial information can also be found at www.sedar.com under the Company’s profile.
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
August 22, 2022
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
June 8, 2022
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
May 9, 2022
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
March 17, 2022
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022